5-Aminolevulinic acid enhances cancer radiotherapy in a mouse tumor model

38Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

5-Aminolevulinic acid (ALA) is a photosensitizer used in photodynamic therapy (PDT) because it causes preferential accumulation of protoporphyrin IX (PpIX) in tumor cells, where it forms singlet oxygen upon light irradiation and kills the tumor cells. Our previous study demonstrated that PpIX enhances generation of reactive oxygen species by physicochemical interaction with X-rays. We investigated the effect of ALA administration with X-ray irradiation of mouse B16-BL6 melanoma cells in vitro and in vivo. ALA facilitates PpIX accumulation in tumor cells and enhances ROS generation in vitro. Tumor suppression significantly improved in animals treated with fractionated doses of radiation (3 Gy × 10; total, 30 Gy) with local administration of 50 mg/kg ALA at 24 h prior to fractional irradiation. These results suggest ALA may improve the efficacy of cancer radiotherapy by acting as a radiomediator. © 2013 Takahashi et al.; licensee Springer.

Cite

CITATION STYLE

APA

Takahashi, J., Misawa, M., Murakami, M., Mori, T., Nomura, K., & Iwahashi, H. (2013). 5-Aminolevulinic acid enhances cancer radiotherapy in a mouse tumor model. SpringerPlus, 2(1), 1–6. https://doi.org/10.1186/2193-1801-2-602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free